1Johanson EH, Jansson PA, Gustafson B, Sandqvist M, Taskinen MR, Smith U, et al. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes. Diabetes Metab Res Rev 2005; 21: 376-81.
2Malmstrom R, Packard C J, Caslake M, Bedford D, Stewart P,Yki-Jarvinen H, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia 1997; 40: 454-62.
3Panarotto D, Remillard P, Bouffard L, Maheux P. Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 2002; 32: 84-92.
4Damsbo P, Marbury TC, Hatorp V, Clauson P, Muller PG. Flexible prandial glucose regulation with repaglinide in patients with type 2 diabetes. Diabetes Res Clin Pract 1999; 45: 31-9.
5Masuda H, Goto M, Tamaoki S, Azuma H. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 1999; 126: 211-8.
6Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51 : 843-6.
7Yasuda S, Miyazaki S, Kanda M, Goto Y, Suzuki M, Harano Y, et al. Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J 2006; 27: 1159-65.
8Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O, et al. Plasma concentrations of asymmetric-dimethyl- arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003; 52: 303-7.
9Vallance P. Importance of asymmetrical dimethylarginine in cardiovascular risk. Lancet 2001; 358: 2096-7.
10Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-6.
5Muggeo M, ZoPPini G, Bonora E, et al. Fasting Plasma glucose variability Predicts 10-year survival of type 2 diabetic Patients, the Verona Diabetes Study. Diabetes Care, 2000,23,45
6Quagliaro L,Piconi L, Assaloni R,et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells. The role of Protein kinase C and NAD(P) H-oxidized activation. Diabetes, 2003,52: 795
7Piconi L, Quagliaro L,Da Ros R. Intermittent high glucose enhances ICAM-1, VCAM-1, E-seleetin and interleukin-6 expression in human umbilical endothelial cells in culture, the role of Poly(ADP-ribose)Polymerase. J Thromb Haemost,2004,2:1453
8Dailey G. New strategies for basal lsulin treatment in type 2 diabetes mellitus. Clin Ther 2004;6(6) :889 -901.
9Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials[J]. Diabetes Metab, 2006,32 (2) :113- 120.
